Page 235 - 2021_02-Haematologica-web
P. 235
The CLL2-BIO trial
A
Figure 3. Progression-free and overall survival. (A) Progression-free survival. (B) Overall survival. FL: patients treated first-line; RR: relapsed/refractory patients
B
haematologica | 2021; 106(2)
549
